PRT-1419

PRT-1419 is a selective oral inhibitor of Mcl-1 that disrupts the formation of the Mcl-1-BIM complex with low nanomolar potency; it has negligible binding to Bcl-2 and Bcl-xL.


Cat. No.: EX-A9776	Purity: >98%

	Chemical structure of PRT-1419

For research only, Do not use for Human!

Size	Unit Price (US$)	Stock	Quantity	Order

Send PO to E-mail:order@excenen.com; or Fax:+86 020 81619670

Discount Request


Purity	>98%

Reference:	[1].Bhagwat, N.; Grego, A.; Gowen-MacDonald, W.; Wang, M.; Cowart, M.; Wu, X.; Zhuo, J.; Combs, A.; Ruggeri, B.; Scherle, P.; et al. Abstract 983: Preclinical characterization of PRT1419, a potent, selective and orally available inhibitor of MCL1. Cancer Res. 2021, 81 (Suppl. S13), 983. [2]. Parrondo, Ricardo D et al. “Updates in the Use of BCL-2-Family Small Molecule Inhibitors for the Treatment of Relapsed/Refractory Multiple Myeloma.” Cancers vol. 14,14 3330. 8 Jul. 2022, doi:10.3390/cancers14143330
CoA	CoA of PRT-1419


		Search